A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Who Have Failed First-Line Therapy
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2016
Price : $35 *
At a glance
- Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 15 Nov 2016 Status changed from active, no longer recruiting to discontinued.
- 12 Aug 2016 Planned End Date changed from 1 Aug 2016 to 1 Oct 2016.
- 12 Aug 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Oct 2016.